Clinical trial
Development and Prognostic Validation of RaFIST: A Radiomics-Based Tool for Intratumoral Fibrosis Stratification in Non-Small Cell Lung Cancer
NCT06908005 is registered in ClinicalTrials.gov with Jinling Hospital, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Development and Prognostic Validation of RaFIST: A Radiomics-Based Tool for Intratumoral Fibrosis Stratification in Non-Small Cell Lung Cancer
- Lead sponsor
- Jinling Hospital, China
- Phase
- Observational
- Overall status
- Completed
- Start date
- April 1, 2024
- Completion date
- March 1, 2025
- Enrollment
- 508 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
lung cancer - non small cell